Subject Index

Absolute risk reduction (ARR), 58
Acceptance and commitment therapy (ACT), 222, 294
Actigraphy, 658
Adrenocorticotropic hormone (ACTH), 213
Affective Control Scale, 129
Alcohol dependence syndrome (ADS), 554
Alcohol use disorders, 151, 550
Alcoholics Anonymous (AA), 552
Alcohol use disorders, 151, 550
Alcohol dependence syndrome (ADS), 554
Affective Control Scale, 129
Adrenocorticotropic hormone (ACTH), 213
Actigraphy, 658
Acceptance and commitment therapy (ACT), 222, 294
Absolute risk reduction (ARR), 58
Addiction, 552
and behavioral treatments for, 568
cross-cultural differences in, 555–557
developmental considerations, 557–558
diagnosis of, 565–567
ethnic/racial differences in, 557
gender differences in, 557
history of, 551–555
mindfulness-based therapies, 569
psychosocial factors, 563–565
psychosomatic families, 492
perfectionism, 490
psychopathology

cognitive ability, 37

case example of, 485
and cognitive dysfunction, 489–490
diagnostic criteria for, 482–485
and emotional dysfunction, 490–491
and environmental factors, 491–493
individual trajectories, 47–48
and weight regain, 482
fear of fatness, 483, 484
fear of weight gain, 485
fear of fatness, 483, 484
fear of weight gain, 485
fluoxetine, 500
fMRI, 487
history of, 485–487
5-HT, 487

process
adherence and fidelity, 65–66
moderators, 64–66
outcomes, 59–63
training and practice, 38–40

Assessment threshold

decision-making, 50
primary intervention, 50
secondary interventions, 50–52
tertiary intervention, 52

Attention-deficit/hyperactivity disorder (ADHD), 47, 369

Attention-mediated hopelessness (AMH), 301–302

Autobiographical memory, 252

Autobiographical Memory Test (AMT), 528

Autonomic nervous system, 212–215

Avoidance behaviors, 255
Avoidant personality disorder (APD), 151
Axis I and II disorders, 17

Basic tendencies, 25
Bayes’ theorem, 53
A Beautiful Mind, 403
Beck Depression Inventory, 40
Beck Depression Inventory–II (BDI-II), 315

Beck’s cognitive theory
automatic thoughts, 295
cognitive distortions, 295–296
core beliefs, 296–297
Behaviors genetics, 565

Behavioral (conditioning) models, 89
Behavioral activation (BA), 294
Behavioral activation system (BAS), 41, 292, 594, 595

Behavioral activation treatment for depression (BATD), 317
Behavioral inhibition, 526
Behavioral inhibition system (BIS), 41, 292, 594, 595

Behavioral marital therapy (BCT), 568
Behavioral weight loss (BWL), 469

Bender Gestalt Test, 40
Benzodiazepines, 222, 267

Binge eating disorder (BED), 449–450
assessments, 464–465
and body dissatisfaction, 462
and body mass, 462–463
and childhood abuse, 464
and cognitive dysfunction, 460–461
dieting, 462
and emotion dysregulation, 459–460

Environmental factors, 463–464
Binge eating disorder (BED) (Continued)
epidemiology
comorbidity, 456
prevalence of, 454–455
genetic risk factors, 456–457
history and diagnostic models of, 452–454
and interoceptive awareness, 462
interventions for, 468–469
and stress, 464
taxometric analysis, 453
treatment for, 468–469
treatment outcomes, 465
See also Anorexia nervosa (AN); Bulimia nervosa (BN)
Bipolar disorder (BD)
age at onset, 368
assessment of, 378–380
biopsychosocial perspective of
epidemiology
and stress, 464
and personality traits, 458–459
medical problems, 451
neurobiological risk factors, 457–458
and comorbidity, 87
prevalence of, 454–455
course, 455
comorbidity, 456
See also
Anorexia nervosa (AN); Borderline personality disorder
Bipolar disorder not otherwise specified (BP-NOS), 366

Borderline personality disorder (BPD), 511
behavioral approaches to, 517–518
case example of, 512–513
clinical assessment approaches
challenges in, 532–533
diagnostic interviews, 529–530
psychometric approaches to, 531–532
Self-Report Questionnaires, 530
Zanarini Rating Scale, 531
clinical outcomes, 533–535
cognitive aspects of, 525–526
executive neurocognition, 526–528
memory systems, 528–529
and comorbidity, 515–516
criteria for, 512
epidemiology and clinical aspects of, 514–515
and functional imaging, 523–524
heterogeneity of, 515–516
history of, 513–514
issues in diagnosis, 529
noradrenergic function, 520
pathogenesis and maintenance of genetics, 518–519
psychobiology, 519–520
neurochemistry, 520–522
neuroimaging studies of, 522
neurotransmitters, 520–522
psychodynamic approaches to, 516–517
psychosocial aspects to attachment theory, 524–525
childhood maltreatment, 524
structural approaches to, 522–524
suicide rate, 511
symptoms of, 511–512
treatment of physiological approaches, 535–536
psychological approaches, 536–538
and twin studies, 518
Borderline Personality Inventory (BPI), 532
Brain-derived neurotrophic factor (BDNF), 304, 307
Brief Social Phobia Scale (BSPS), 167
Brown Assessment of Beliefs Scale (BABS), 93
Bulimia nervosa (BN), 446–448
assessment, 464–465
biological view, 453
and body dissatisfaction, 462
and body mass, 462–463
case study of, 451–452
and childhood abuse, 464
and cognitive dysfunction, 460–461
diet, 462
and emotion dysregulation, 459–460
environmental factors of, 463–464
epidemiology
comorbidity, 456
course of, 455
prevalence of, 454–455
family, 463
genetic risk factors, 456–457
history and diagnostic models of, 452–454
and interoceptive awareness, 462
interventions for, 466–468
medical complications, 448–449
neurobiological risk factors, 457–458
and personality traits, 458–459
and stress, 464
taxometric analysis, 453
treatment for, 466–468
treatment outcomes, 465
See also Anorexia nervosa (AN); Binge eating disorder (BED)

Catatonia, 406
Center for Epidemiologic Studies Depression Scale (CES-D), 316
Cerebrospinal fluid (CSF), 520
Child Behavior Checklist (CBCL), 38
Children’s Eating Attitudes Test (Chi-EAT), 465
Cholecystokinin (CCK), 113, 449
Cialis, 625
Circadian rhythm disorders, 663
Classical conditioning, 88
Clinical neuroscience of addiction, 565
Clinically significant change model, 61–62
Clinician-Administered PTSD Scale (CAPS), 254, 261
Cognitive behavioral analysis system of psychotherapy (CBASP), 351–352
Cognitive behavior therapy (CBT)
and alcohol use disorders, 568
and anorexia nervosa, 499
and binge eating disorder, 468–469
and bipolar disorder, 385–386
and bulimia nervosa, 466–468, 486
clinical trials, 466–467
generalized anxiety disorder, 130–132
insomnia, 658–662
major depressive disorder, 290, 294, 317
panic disorder, 219–222
posttraumatic stress disorder, 264–265
schizophrenia and psychosis spectrum, 430
social anxiety disorder, 169, 171
Cognitive deficit models
inhibitory deficits, 89
reality monitoring, 89
synthesis, 89
Cognitive inhibition, 526
Cognitive therapy (CT), 170
CT vs. ERP, 102
delivery of, 100–101
Cognitive-behavioral conjoint therapy (CBCT), 266
Cognitive-remediation therapy (CRT), 502
Collaborative care management (CCM), 383
COMBINE Study Research Group, 571
Combined behavioral intervention (CBI), 571
Communication deviance (CD), 410
Conditioned stimulus and an unconditioned response (CS-UR), 596
Conservation of resources (CSR), 259
Cornell Dysthymia Rating Scale, 350
Cortical arousal, 653
Corticotropin releasing factor (CRF), 249, 564
<table>
<thead>
<tr>
<th>Subject Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Course and Outcome of Bipolar Youth (COBY) study, 366</td>
</tr>
<tr>
<td>Cue-exposure therapy, 568</td>
</tr>
<tr>
<td>Culture-bound syndromes, 18</td>
</tr>
<tr>
<td>Cyclic guanosine monophosphate (cGMP), 624</td>
</tr>
<tr>
<td>Cyclothymia, 366</td>
</tr>
<tr>
<td>D-cycloserine (DCS), 172, 268</td>
</tr>
<tr>
<td>Dehydroepiandrosterone (DHEA), 250</td>
</tr>
<tr>
<td>Deletion syndrome (DS), 414</td>
</tr>
<tr>
<td>Dementia praecox, 406</td>
</tr>
<tr>
<td>Depression</td>
</tr>
<tr>
<td>genetic vulnerability, 371</td>
</tr>
<tr>
<td>pharmacotherapy treatment, 381–382</td>
</tr>
<tr>
<td>psychosocial predictors, 375–376</td>
</tr>
<tr>
<td>MDD (see Major depressive disorder (MDD))</td>
</tr>
<tr>
<td>Depressive personality disorder. See Dysthymia and chronic depression</td>
</tr>
<tr>
<td>Dexamethasone monosuppression (DST-NS), 309</td>
</tr>
<tr>
<td>Dexamethasone suppression test (DST), 309, 348</td>
</tr>
<tr>
<td>Diagnostic and Statistical Manual of Mental Disorders (DSM-I), 14–15</td>
</tr>
<tr>
<td>Diagnostic and Statistical Manual of Mental Disorders (DSM-II), 14–15</td>
</tr>
<tr>
<td>Diagnostic and Statistical Manual of Mental Disorders (DSM-III), 15–17</td>
</tr>
<tr>
<td>Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 18–19</td>
</tr>
<tr>
<td>Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), 19</td>
</tr>
<tr>
<td>anorexia nervosa (see Anorexia nervosa (AN))</td>
</tr>
<tr>
<td>binge eating disorder (see Binge eating disorder (BED))</td>
</tr>
<tr>
<td>bipolar disorder, 365</td>
</tr>
<tr>
<td>bulimia nervosa (see Bulimia nervosa (BN))</td>
</tr>
<tr>
<td>dysthymia and chronic depression, 340</td>
</tr>
<tr>
<td>goal of, 445</td>
</tr>
<tr>
<td>insomnia, 650</td>
</tr>
<tr>
<td>major depressive disorder, 286</td>
</tr>
<tr>
<td>OCD (see Obsessive-compulsive disorder (OCD))</td>
</tr>
<tr>
<td>panic disorder (see Panic disorder)</td>
</tr>
<tr>
<td>PTSD (see Posttraumatic stress disorder (PTSD))</td>
</tr>
<tr>
<td>SAD (see Social anxiety disorder (SAD))</td>
</tr>
<tr>
<td>See also criteria and history of individual disorders</td>
</tr>
<tr>
<td>Diagnostic Interview for Borderlines, Revised (DIB-R), 530</td>
</tr>
<tr>
<td>Diagnostic Interview Schedule (DIS), 261</td>
</tr>
<tr>
<td>Dialectical behavior therapy (DBT), 293, 536</td>
</tr>
<tr>
<td>Diathesis-stress model, 296, 404</td>
</tr>
<tr>
<td>Diffusion tensor imaging (DTI), 419</td>
</tr>
<tr>
<td>Directed masturbation (DM), 636</td>
</tr>
<tr>
<td>Divalproex sodium, 381</td>
</tr>
<tr>
<td>Dopamine, 153, 251, 372, 420–421</td>
</tr>
<tr>
<td>Dopamine transporter (DAT1) gene, 519</td>
</tr>
<tr>
<td>Dorsolateral prefrontal cortex (DLPFC), 523</td>
</tr>
<tr>
<td>Double-bind theory, 410</td>
</tr>
<tr>
<td>Dual-Control Model, 628</td>
</tr>
<tr>
<td>Dyspareunia assessment, 640</td>
</tr>
<tr>
<td>biological factors, 638–639</td>
</tr>
<tr>
<td>cognitive behavioral therapy, 640</td>
</tr>
<tr>
<td>definition, diagnosis, and prevalence of, 637–638</td>
</tr>
<tr>
<td>electromyographic biofeedback, 640</td>
</tr>
<tr>
<td>psychological factors, 639</td>
</tr>
<tr>
<td>treatment of, 640–641</td>
</tr>
<tr>
<td>Dysphoria and chronic depression assessment of, 349–350</td>
</tr>
<tr>
<td>case example of, 335–336</td>
</tr>
<tr>
<td>chronic stress, 346</td>
</tr>
<tr>
<td>classification of, 336–340</td>
</tr>
<tr>
<td>cognitive factors, 344</td>
</tr>
<tr>
<td>and comorbidity, 341</td>
</tr>
<tr>
<td>course and prognosis of, 341–342</td>
</tr>
<tr>
<td>diagnostic criteria, 334–335</td>
</tr>
<tr>
<td>familial aggregation/genetics, 346–347</td>
</tr>
<tr>
<td>and impairment, 341</td>
</tr>
<tr>
<td>interpersonal factors of, 345</td>
</tr>
<tr>
<td>maltreatment and early adversity, 343</td>
</tr>
<tr>
<td>neuroendocrinology, 347</td>
</tr>
<tr>
<td>and neuroimaging, 348–349</td>
</tr>
<tr>
<td>in older adults, 342–343</td>
</tr>
<tr>
<td>overview of, 352–355</td>
</tr>
<tr>
<td>personality/temperament, 344</td>
</tr>
<tr>
<td>prevalence rates of, 340</td>
</tr>
<tr>
<td>and sleep electrophysiology, 348</td>
</tr>
<tr>
<td>treatment acute-phase treatment, 351–352</td>
</tr>
<tr>
<td>continuation and maintenance treatment, 352</td>
</tr>
<tr>
<td>of nonresponders, 352</td>
</tr>
<tr>
<td>in youth, 342</td>
</tr>
<tr>
<td>Dyphphoric disorder. See Dysthymia and chronic depression</td>
</tr>
<tr>
<td>Eating Attitudes Test (EAT), 494</td>
</tr>
<tr>
<td>Eating disorder (ED)</td>
</tr>
<tr>
<td>AN (see Anorexia nervosa (AN))</td>
</tr>
<tr>
<td>assessment, 464–465</td>
</tr>
<tr>
<td>BED (see Binge eating disorder (BED))</td>
</tr>
<tr>
<td>BN (see Bulimia nervosa (BN))</td>
</tr>
<tr>
<td>cognitive dysfunction, 460–461</td>
</tr>
<tr>
<td>EDE-Q, 464</td>
</tr>
<tr>
<td>emotion dysregulation, 459–460</td>
</tr>
<tr>
<td>environmental factors</td>
</tr>
<tr>
<td>childhood sexual abuse/stress, 464</td>
</tr>
<tr>
<td>family, 463</td>
</tr>
<tr>
<td>sociocultural pressure, 463</td>
</tr>
<tr>
<td>epidemiology comorbidity, 456</td>
</tr>
<tr>
<td>course, 455</td>
</tr>
<tr>
<td>prevalence of, 454–455</td>
</tr>
<tr>
<td>genetic risk factors, 456–457</td>
</tr>
<tr>
<td>neurobiological risk factors, 457–458</td>
</tr>
<tr>
<td>overvaluation, 454</td>
</tr>
<tr>
<td>overvaluation of thinness, 482</td>
</tr>
<tr>
<td>parental obesity, 463</td>
</tr>
<tr>
<td>personality traits, 459</td>
</tr>
<tr>
<td>impulsivity, 458</td>
</tr>
<tr>
<td>obsessuality, 458–459</td>
</tr>
<tr>
<td>perfectionism, 459</td>
</tr>
<tr>
<td>prevention of, 470</td>
</tr>
<tr>
<td>risk factors body dissatisfaction, 462</td>
</tr>
<tr>
<td>body mass, 462–463</td>
</tr>
<tr>
<td>dieting, 462</td>
</tr>
<tr>
<td>interoceptive awareness, 462</td>
</tr>
<tr>
<td>transdiagnostic model, 454</td>
</tr>
<tr>
<td>Eating Disorder Examination (EDE), 464, 493</td>
</tr>
<tr>
<td>Eating Disorder Inventory (EDI), 464, 494</td>
</tr>
<tr>
<td>Eating disorder not otherwise specified (EDNOS), 484</td>
</tr>
<tr>
<td>Ego-Oriented Individual Therapy (EOIT), 498</td>
</tr>
<tr>
<td>Ejaculation latency, 630</td>
</tr>
<tr>
<td>Electroconvulsive shock therapy (ECT), 290</td>
</tr>
<tr>
<td>Electroencephalogram (EEG), 417</td>
</tr>
<tr>
<td>Elemental Psychopathy Assessment (EPA), 593</td>
</tr>
<tr>
<td>Emotional overinvolvement (EOI), 534</td>
</tr>
<tr>
<td>Emotional processing theory, 253</td>
</tr>
<tr>
<td>Emotional Stroop Test, 527, 528</td>
</tr>
<tr>
<td>Employee assistance programs (EAP), 553</td>
</tr>
<tr>
<td>Endophenotypes, 5</td>
</tr>
<tr>
<td>Endophenotypic markers, 26–27</td>
</tr>
<tr>
<td>Erectile dysfunction (ED) assessment of, 625</td>
</tr>
<tr>
<td>biological factors, 624</td>
</tr>
<tr>
<td>definition of, 625–624</td>
</tr>
<tr>
<td>diagnosis of, 623–624</td>
</tr>
<tr>
<td>prevalence of, 623–624</td>
</tr>
<tr>
<td>psychological factors, 624</td>
</tr>
<tr>
<td>spectatoring, 624</td>
</tr>
<tr>
<td>treatment of, 625–626</td>
</tr>
<tr>
<td>Event history analysis, 48–49</td>
</tr>
<tr>
<td>Evidence-based medicine (EBM) threshold model, 52</td>
</tr>
<tr>
<td>Exercise anorexia, 48</td>
</tr>
<tr>
<td>Exophenotypes, 5</td>
</tr>
<tr>
<td>Expectancy theory, 559–560</td>
</tr>
<tr>
<td>Exposure and response prevention (ERP) delivery of, 99–100</td>
</tr>
<tr>
<td>efficacy of, 100–101</td>
</tr>
<tr>
<td>mechanisms of change, 100</td>
</tr>
<tr>
<td>Expressed emotion (EE), 374, 411, 534</td>
</tr>
<tr>
<td>Eye movement desensitization and reprocessing (EMDR), 266</td>
</tr>
<tr>
<td>Family-based therapy (FBT)</td>
</tr>
<tr>
<td>and anorexia nervosa, 495, 500, 502</td>
</tr>
<tr>
<td>and bulimia nervosa, 498</td>
</tr>
<tr>
<td>Family-focused treatment (FFT), 384–385</td>
</tr>
<tr>
<td>Fear potentiated startle (FPS), 598</td>
</tr>
<tr>
<td>Fearless Dominance (FD), 602</td>
</tr>
<tr>
<td>Feighner Diagnostic Criteria, 554</td>
</tr>
<tr>
<td>Female orgasmic disorder (FOD)</td>
</tr>
<tr>
<td>assessment of, 636</td>
</tr>
<tr>
<td>biological factors, 634</td>
</tr>
</tbody>
</table>
Female orgasmic disorder (FOD) (Continued)
definition, diagnosis, and prevalence of, 633–634
psychological factors, 635–636
treatment of, 636–637
Female sexual arousal disorder (FSAD)
assessment of, 628–629
biological factors, 627–628
definition, diagnosis, and prevalence of, 626–627
EROS clitoral therapy device, 629
genital sexual arousal disorder, 627
placebo effect, 629
psychological factors, 628
subjective sexual arousal disorder, 627
treatment of, 629
Fight/flight system (FFS), 41
Five-factor model (FFM), 25, 593
First-episode psychosis (FEP), 426
Five-factor model (FFM), 25, 593
First-episode psychosis (FEP), 426
Food and Drug Administration (FDA), 570
Five-factor model (FFM), 25, 593
Five-factor model (FFM), 25, 593
Food and Drug Administration (FDA), 570
Friend’s program, 172
Functional anisotropy (FA), 419
Functional magnetic resonance imaging (fMRI), 212, 373, 560
Gamma-aminobutyric acid (GABA), 113, 250, 563
General Behavior Inventory (GBI), 350, 379
Generalized anxiety disorder (GAD)
ADIS-IV, 126–127
biological interventions, 132–134
cognitive and behavioral correlation avoidance theories of worry, 119–120
information processing theories, 117–119
intolerance of uncertainty, 120–121
life events, 115
metacognition, 121–123
probability overestimation and catastrophizing, 117
problem-solving ability, 116–117
cognitive behavior therapy, 130–132
comorbidity, 112
diagnostic considerations, 108–109
emotional correlation
depression, 123
environmental and family factors, 125–126
“mood-as-input” approach, 124
rumination and obsessions, 124
social phobia and nonanxious control, 123
epidemiology and descriptive psychopathology, 110–112
historical perspectives, 109–110
neurobiology
amygdala volumes, 114
cholecystokinin, 113
chronic worry, 115
cortisol levels, 113
gamma-aminobutyric acid, 113
norepinephrine, 113
serotonin, 113
psychological interventions, 130
SCID-IV, 127
self-report measures
Generalized Anxiety Disorder Questionnaire, 127
Generalized Anxiety Disorder—7-Item Scale, 128
ongoing and follow-up assessment, 129
theoretical constructs, 128–129
worry severity and content, 128
Genome-wide association studies (GWAS), 304
Gerstmann’s syndrome, 2
Global Study of Sexual Attitudes and Behaviors, 623
Glutamate, 373, 421
Goal dysregulation, mania, 376–377
Glutathione, 373, 421
Hamilton Rating Scale for Depression (HAM-D), 316, 350
Heart rate variability abnormalities, 214
Hebbelphrenia, 406
Hoarding, 87
Hopelessness depression, 298
HPA axis dysfunction, 212–215
5-HTTLPR polymorphism, 210
5-Hydroxyindolacetic acid (5-HIAA), 520
Hypercortisolemia, 663
Hypersomnia, 663
Hypoxic sexual desire disorder (HSDD) androgens, 618
assessment of, 621
biological factors, 618–619
childhood sexual abuse, 620
definition, diagnosis, and prevalence of, 616–618
estrogens, 618
female sexual interest/arousal disorder, 617
oral contraception, 618
psychological factors, 618–619
testosterone, 618, 619
treatment, 621–623
cognitive restructuring, 622
psychological treatment, 622
sensate focus, 622
testosterone, 621
Hypogonadism, 621
Hypogonadistic Personality Scale, 379
Hypothalamic-pituitary-adrenal (HPA) axis, 249, 347, 521–522
functional organization of, 308–309
pathophysiology of, 309–310
Ideal body weight (IBW), 483
Impulsive Antisociality (IA), 602
Incremental validity, 43
Initial Exploratory Factor Analysis, 588
Insomnia
assessment of, 656–658
case examples of, 650–651
circadian rhythm, 654
cognitive model, 653
definition, diagnosis, and prevalence of, 653
emotion, role of, 655
environmental factors, 656
epidemiology of, 652
history of, 651–652
hybrid models, 654–655
hyperarousal models, 653
neurocognitive model, 653–654
pharmacological interventions, 661–662
psychological interventions, 658–662
quantitative criteria, 650
sleep homeostasis, 654
stimulus control model, 653
symptoms and diagnostic criteria, 650
three-factor model, 652
Interference control, 526
International Classification of Sleep Disorders (ICSD), 650
International Personality Disorder Examination (IPDE), 530
International Research Group on Gender and Alcohol, 556
Interpersonal and social-rhythm therapy (IPSRT), 386–387
Interpersonal psychotherapy (IPT), 351, 466, 498
Intimate partner violence (IPV), 265
Intolerance of Uncertainty Scale, 129
Johnson, V. E., 617
Keane-PTSD Scale, 263
Kiddie Schedule for Affective Disorders and Schizophrenia, Present and Lifetime Version (KSADS-PL), 378
Labeling theory, 10
Lamotrigine, 267
Latent class analysis (LCA), 45
Laumann, E. O., 617
Levitra, 625
Liebowitz Social Anxiety Scale (LSAS), 167
Likelihood of help versus harm (LHH), 58
Limbic-hypothalamic-pituitary-adrenal (LHPA) axis, 113
Lithium, 380
Longitudinal Interval Follow-Up Evaluation (LIFE), 60, 315, 380
Major depressive disorder (MDD), 320
assessment of
clinical interviews, 314–315
clinical rating scales, 316
self-report measures, 315–316
behavioral models of, 291–294
behavioral treatments, 317
brain imaging, 311–312
case example of, 289–290
cognitive behavior therapy, 317
cognitive models of
attentional deficits, 301–302
Beck’s cognitive theory, 294–297
hopelessness theory, 298
information processing, learning, and memory, 299–300
learned helplessness model, 297–298
negative cognitive style, 302–303
ruminative, 300–301
diagnostic criteria, 286–288
genetics of, 303–305
integrative model of, 313–314
neurochemistry of, 305–307
neuroendocrinology of, 307–310
overview of, 285–286
prevalence rates of, 289
prevention of, 319–320
psychology of, 290
psychoneuroimmunology of, 310–311
somatic treatments, 318–319

See also Dysthymia and chronic depression

Major depressive episode (MDE), 16, 335
Mania and bipolar disorder
creativity, 370
pharmacotherapy treatment, 380–381
phenomenology of, 366–367
psychotherapy treatment, 380–381
psychosocial predictors of reward sensitivity, 376–377
sleep deprivation, 377–378

The Mask of Sanity, 584
Masters, W. H., 617

Medical Sub-Heading (MeSH), 55

Mental disorder
biological model, 12
harmful dysfunctions, 13
medical intervention, 13
Roschian analysis, 13–14
statistical model, 11
subjective distress model, 12

Mental Measurements Yearbooks, 40
Meta-Cognitions Questionnaire (MCQ), 128
3-Methoxy-4-hydroxyphenylglycol (MHPG), 520
Mindfulness meditation, 222
Mindfulness-based stress reduction (MBSR), 222
Minimum Average Partialls, 44
Minnesota Multiphasic Personality Inventory (MMPI), 263, 531
Minor physical anomalies (MPAs), 416
Mirtazapine, 267
Mississippi Scale for Combat-Related PTSD, 262
Monamine oxidase inhibitors (MAOIs), 172
Monitoring the Future (MFT), 557
Monoamine oxidase inhibitors (MAOIs), 267, 305, 318–319
Montgomery-Asberg Depression Rating Scale (MADRS), 316

Mood Disorders Questionnaire (MDQ), 379
Morgan-Russell assessment battery of Anorexia nervosa, 494
Mothers Against Drunk Driving, 552
Motivational (or affective) inhibition, 527
Motivational enhancement therapy (MET), 568–570
Multidimensional Personality Questionnaire (MPQ), 601, 602

N-methyl-D-aspartic acid (NMDA) subtype receptors, 421
Naltrexone, 570, 571
Narcolepsy, 663
Narrative exposure therapy (NET), 266
National Comorbidity Survey Replication (NCS-R), 196, 366
National Epidemiological Survey on Alcohol and Related Conditions (NESARC), 550, 551, 568
National Institute on Alcohol Abuse and Alcoholism, 558

Nausea, 4
Negative emotionality (NE), 344
Neuropeptide Y (NPY), 249, 564
Night eating syndrome (NES), 453
Nocturnal panic attacks, 194
Nomogram, 56–57
Nonrapid eye movement (NREM) sleep, 649–650
Noradrenaline (NE), 113, 307, 628
Noradrenaline transporter (NET), 306
Norwegian Universal Prevention Program for Social Anxiety (NUPP-SA), 172
Nosology, 46
Nucleus accumbens (NAC), 563
Number needed to harm (NNH), 58
Number needed to treat (NNT), 58
Number of awakenings after sleep onset (NWAKE), 656

Objective binge episodes (OBEs), 447, 465
Obsessive-compulsive disorder (OCD), 2
assessment
Clinician-Rated Severity Scales, 92–93
diagnostic interviews, 92
functional assessment, 95–98
self-report measures, 93–95
biological treatments
neurosurgical treatment, 102
serotonin reuptake inhibitors, 102
definition, 80
DSM-5 diagnostic criteria, 80–82
neurobiologiical models
evaluation of, 92
serotonin hypothesis, 91
structural models, 91–92
prevalence and epidemiology, 88
psychological models
cognitive behavioral models, 89–91
cognitive deficit models, 89
learning models, 88
psychological treatment
cognitive therapy, 101–102
ERP, 99–101
signs and symptoms
accommodation, 85
avodance, 84
body dysmorphic disorder, 87
compulsive rituals, 82–83
hoarding, 87
obsessions symptoms, 82
OCBD, 87–88
poor insight, 84

relationship stress and conflict, 85–86
subtypes and dimensions, 84
tic disorders, 85
Obsessive-compulsive personality disorder (OCPD), 87–88
Obstetrical complications (OCs), 415–417
Onodansetron, 571
Operant conditioning, 88
Orgasmic disorders
female, 633–637
male, 630
premature ejaculation, 630–633
Osteoporosis, 483

Panic disorder
assessment
behavioral test, 217–218
clinical rating scales, 216
interviews, 215–216
neurobiological, 218
ongoing assessment, 218
self-report and behavioral measures, 216–217
behavioral features, 198
biological features
genetics, 209–211
neurocircuitry, 211–215
biological intervention, 222–223
case example, 194–196
cognitive features, 201–202
description of, 193–197
diagnostic criteria, 193–194
emotional features, 202
environmental factors
childhood abuse/illness, 205–206
early caregiving and infant attachment, 203–204
parenting, 204–205
stress, 206–207
tetiological models, 207–209
experiential avoidance, 200–201
history of, 196
interceptive avoidance, 198
prevalence/epidemiology, 196–197
prevention, 223–224
psychological intervention, 219–222
safety behaviors, 199–200
symptoms, 193–194

Panic Disorder Severity Scale (PDSS), 216
Paranoia, 406
Parasympathetic nervous system arousal (PNS), 628
Parenting, 204–205
Partial NMDA glutamatergic receptor, 268
Passive Avoidance Task, 527
Patient Outcomes Research Team (PORT), 429
Periodic limb movement disorder (PLMD), 663
Persistent depressive disorder, 334
Personal Beliefs and Reactions Scale (PBRS), 254
Personality Assessment Inventory (PAI), 531

Subject Index
Personality Disorders Questionnaire (PDQ-4), 530
Personality theory, 561–562
Phenelzine, 267
Phosphodiesterase type 5 (PDE5) inhibitors, 625
Phosphodiesterases (PDEs), 624
Polysonomography (PSG), 657–658
Positive emotionality (PE), 344
Positron emission tomography (PET), 373, 487, 523
Positivistic stress disorder (PTSD) assessment
 diagnostic interviews, 261–262
physiological assessment, 263–264
self-report measures, 262–263
traumatic events, 260–261
behavioral factors, 255–256
case example, 246–247
cognition and memory
accommodation, 253
assimilation, 253
cognitive processes/cognitive content, 251
flashback, 253
maladaptive coping strategies, 252
memory vividness and accessibility, 253
overaccommodation, 253
situationally accessible memories, 252
Stroop paradigm, 254
thought-suppression paradigms, 254
traumatic events and victimization, 252
verbally accessible memories, 251
comorbidity and personality, 256–258
diagnostic criteria, 244–246
emotional factors, 256
environmental factors
conservation of resources, 259
intimate relationships, 258
social support and additional life stress, 258
epidemiology, 247–249
internalizing/externalizing model, 257
prevalence, 247–249
psychobiological dysfunction
brain structures, 251
dopamine, 251
gamma-aminobutyric acid, 250
hypothalamic-pituitary-adrenal axis, 249
noradrenergic system, 249
serotonin, 250
psychopharmacological treatment
antiadrenergics, 267
antidepressants, 267
atypical antipsychotics, 268
D-cycloserine, 268
GABAergic agonists, 267
mood stabilizers, 267
sertraline and paroxetine, 266
psychosocial treatment
brief eclectic psychotherapy, 266
cognitive behavior therapy, 264–265

cognitive-behavioral conjoint therapy, 266
eye movement desensitization and reprocessing, 266
narrative exposure therapy, 266
Prazosin, 267
Premature ejaculation (PE)
assessment of, 632
biological factors, 631
definition, diagnosis, and prevalence of, 630–631
pause technique, 632
psychological factors, 631–632
squeeze technique, 632
treatment of, 632–633
Primary and Secondary Psychopathy Scales (SRPS), 592
Primary intervention/universal prevention, 50
Prodromal syndrome, 423–424
Project MATCH, 569–570
Propranolol, 267
Provoked vestibulodynia (PVD), 638–640
Psychiatric diagnosis
bipolar I disorder, 4
bipolar II disorder, 4
classification
algorithm, 16–17
attenuation paradox, 22–23
categorical model, 23–24
comorbidity, 20–21
culture-bound syndromes, 18
dimensional approach, 24–26
DSM-I, 14–15
DSM-II, 14–15
DSM-III, 15–17
DSM-III-R, 18–19
DSM-IV, 18–19
DSM-5, 19
dendophenotypic markers, 26–27
hierarchical exclusion rules, 16–17
interviews, 17
monothetic approach, 18
multiaxial approach, 16–17
neurocognitive approach, 18
polythetic approach, 18
theoretical diagnosticism, 17
communication, 3
construct validation, 5, 6
mental disorder
biological model, 12
harmful dysfunctions, 13
medical intervention, 13
Roschian analysis, 13–14
statistical model, 11
subjective distress model, 12
misconception, 6–11
open concepts, 5
schizophrenia patient, 4
terminology, 1–3
validity, 4
Psychopathic Personality Inventory (PPI), 592
Psychopathy assessment of, 586–590
diagnostic criteria for, 583–586
measures of, 590–593
overview, 605
prevalence of, 594
psychological models and somatic factors
fearlessness, fear-conditioning, and amygdala abnormalities, 594–597
genetics, 600–602
response modulation and attention, 597–600
treatment of, 602–604
Psychopathy Checklist (PCL), 262
Screening Version (PCL-SV), 586, 590, 592
Youth Version (PCL-YV), 586, 590–591
Psychopathy Checklist–Revised (PCL-R)
affective/interpersonal factor, 588
criminal justice system, 588
development of, 586
generalizability, 589–590
impulsive/antisocial lifestyle factor, 588
items, 587
violence, 587
Psychopathy Resemblance Index (PRI), 593
Psychostimulant theory of addiction, 563–564
PTSD Symptom Scale–Self Report (PSS-SR), 262
Q-methods, 45–47
Quality of life (QOL), 218
Quick Inventory of Depression Symptomatology (QIDS), 316
Rapid eye movement (REM) sleep, 649
Rational Recovery framework, 552
Receiver operating characteristic (ROC) analysis, 54
Reliable change index (RCI), 61
Research Domain Criteria (RDoC), 41
Response modulation hypothesis (RMH), 597–600
Response styles theory (RST), 300–301
Restless legs syndrome (RLS), 663
Revised NEO Personality Inventory (NEO PI-R), 532
Roschian analysis, 13–14
Safety behaviors, 199–200
Scale of Prodromal Symptoms (SOPS), 426
Schedule for Affective Disorders and Schizophrenia (SADS), 378
Schedule for Nonadaptive and Adaptive Personality, Second edition (SNAP-2), 531
Situationally accessible memories (SAM), 252
Sleep apnea, 663
Sleep diary, 657
Sleep disorders
circadian rhythm disorders, 663
hypersomnia, 663
insomnia, 649 (see also Insomnia)
narcolepsy, 663
overview of, 664–665
periodic limb movement disorder, 663
restless legs syndrome, 663
sleep apnea, 663
Sleep onset latency (SOL), 656
Sleep quality (SQ), 657
Social anxiety disorder (SAD)
assessment
clinical interviews, 166–167
clinical rating scales, 167–168
neurobiological assessment, 169
ongoing assessment and follow-up, 169
self-report measures, 168–169
biological interventions, 171–172
case examples, 148
computer-based self-help treatments/apps, 17b
description of, 147–149
environmental factors
family environment, 161–165
peer environment, 165–166
genetics, 152–153
history, 148–149
Internet-based self-help programs, 176
neurobiology, 152–153
prevention, 172–174
psychological and psychosocial dysfunction
attentional bias, 155–157
imagery and visual memory biases, 159–160
impaired social functioning, 154–155
information processing biases, 161
judgment and interpretation bias, 157–159
psychological interventions, 169–171
safety behaviors, 174
symptoms and criteria, 147
therapeutic interventions, 175
Social learning theory (SLT), 562–563
Social phobia, 148
Specialist supportive individual therapy (SSIT), 498, 501
Stanley Foundation Network study, 369
Stimulus control model, 653
Stress, 206–207
Stress Inoculation Therapy (SIT), 264
Stress sensitization model, 375
Stress-response dampening (SRD), 560
Stroop paradigm, 117
Structured Clinical Interview for DSM-IV (SCID-IV), 127, 261, 314–315
Structured Clinical Interview for DSM-IV Personality Disorders (SCID-IV), 530
Structured Diagnostic Interview for DSM-IV (SCID), 378–379
Structured Interview for DSM-IV Personality Disorders (SIDP-IV), 530
Subjective binge episodes (SBEs), 447
Subjective distress model, 12
Substance use disorders, 151
Sympathetic nervous system arousal (SNS), 628
Symptom Checklist-90-R (SCL-90-R), 262
Syphilis, 405
Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), 387
Tadalaflı, 625
Taijin kyofusho, 19
Tension reduction therapy, 560–561
Tertiary interventions, 52
Textbook of Psychiatry, 286
Three-factor model, 652
Three-P model, 652
Topiramate, 571
Toronto Alexithymia Scale, 129
Total sleep time (TST), 656
Tourette’s syndrome, 85
Transference-Focused Psychotherapy (TFP), 537
Trauma Symptom Inventory (TSI), 263
Treatment as usual (TAU), 537
Treatment of Depression Collaborative Research Project (TDCRP), 318
Treatment threshold
clinical diagnosis, 50
decision-making, 50
primary intervention, 50
secondary interventions, 50–52
tertiary intervention, 52
Treponema pallidum, 405
Tricyclic antidepressants (TCAs), 267, 318–319, 351
Trier Social Stress Test (TSST), 213
Two-factor theory, 255
Type 1 worry, 122
Type 2 worry, 122
Unconditioned Stimulus (UCS), 595
Unipolar depression, 371, 375–376
Vaginismus
assessment of, 642
biological factors, 641–642
definition, diagnosis, and prevalence of, 641
electromyographic biofeedback, 642
### Subject Index

- **Vaginismus (Continued)**
  - psychological factors, 642
  - treatment of, 642–643
- Venlafaxine, 267
- Verbally accessible memories (VAM), 251
- Verdanafil, 625
- Viagra, 624–626
- Vulvodynia, 638

- **Wake after sleep onset (WASO)**, 656
- **Wechsler Intelligence Scale for Children (WISC)**, 37
- **Wisconsin Card Sort Task (WCST)**, 528
- Yale-Brown Obsessive Compulsive Scale (Y-BOCS), 92, 93
- Youth Psychopathic Traits Inventory (YPI), 591
- Youth Psychopathic Traits Inventory–Child Version (YPI-CV), 591
- Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD), 531